Monday, April 30, 2007
UPDATE: NOT LOTTO: INSM
| INSM Insmed releases positive results from IPLEX Phase II HIV-Associated adipose redistribution syndrome clinical study (1.02 ) | |
| Co announces positive results from a Phase II investigator-sponsored clinical study of the company's drug IPLEX in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome. Preliminary results from the study showed that three months of 0.5 mg/kg/day IPLEX treatment in seven patients increased IGF-I levels 3-fold and was associated with significant improvements in fasting glucose levels, the amount of insulin secreted during an oral glucose tolerance test, and overall insulin sensitivity. Moreover, there was a significant reduction in trunk fat and a positive downward trend in waist circumference when compared to baseline. Lipid profiles also tended to improve. Notably, normal glucose tolerance was restored in half of the six patients diagnosed with impaired glucose tolerance at the start of the study. These I.G.T patients also experienced a significant decrease in visceral adipose tissue. |
Comments:
<< Home
I'm glad MVIS is coming back off near the $3.98-$4.03 range, that is about where the neckline is, it seems to be a perfect setup for a breakout to new highs, any "chart chomper" will tell you that.
Post a Comment
<< Home
